Japanese Billionaire Masayoshi Son’s Latest Portfolio: Top 5 Stock Picks

3. AbCellera Biologics Inc. (NASDAQ:ABCL)

SB Management’s Stake Value: $140  million

Percentage of SB Management’s Portfolio: 13.88%

Number of Hedge Fund Holders: 18

SB Management looks bullish over the future fundamentals of AbCellera Biologics Inc. (NASDAQ:ABCL). The firm first invested in the company during the December quarter of 2020, lifted its stake further in the March quarter, and has since left its stake unchanged. The Vancouver, British Columbia-based company is researching and developing human antibodies.

Of the 924 13F-filing hedge funds tracked by Insider Monkey, AbCellera was in 18 portfolios as of December 31, down from 21 positions in the previous quarter. Baker Bros. Advisors was a leading stakeholder in the company.